Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Finerenone in patients with focal segmental glomerulosclerosis: A FIND-CKD analysis
Finerenone slowed the progression of kidney function decline in participants with FSGS
Finerenone significantly slowed total eGFR decline from baseline to month 32 versus placebo
The effect was consistent between participants with primary and secondary FSGS
Finerenone showed favorable effects across clinical and urinary protein outcomes
Kidney and CV outcome HRs favored finerenone, but the differences were not nominally significant
Finerenone reduced UACR and UPCR at month 12
- More participants achieved UACR <500 mg/g and UPCR <700 mg/g at month 12 with finerenone than with placebo
Finerenone was well tolerated, with a safety profile broadly comparable to placebo
Overall rates of TEAEs, including hyperkalemia, were similar between treatment groups
- Serious TEAEs were not more frequent with finerenone, and no fatal TEAEs occurred
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
